Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Status:
Recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the
treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral
ulcers associated with Behçet's disease (BD) through week 12.